keyword
https://read.qxmd.com/read/33203615/dress-syndrome-following-furosemide-administration-an-unusual-association
#21
JOURNAL ARTICLE
N Ben Fadhel, H Ben Romdhane, A Chaabane, H Belhadj Ali, N A Boughattas, K Aouam, N Ben Fredj
INTRODUCTION: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe and rare adverse drug reaction. Several drugs are known to induce DRESS. Furosemide, a sulfonamide loop diuretic drug, is known to induce hypersensitive reactions such as bullous eruptions, acute generalized exanthematous pustulosis and lichenoid eruptions, but rarely DRESS. We describe herein a case of furosemide-induced DRESS that recurred after bumetanide administration. CASE REPORT: A 67-year-old man was admitted to the nephrology department for hypertension, gout and chronic renal failure...
November 14, 2020: Néphrologie & Thérapeutique
https://read.qxmd.com/read/31985336/late-diagnosis-of-lesch-nyhan-disease-complicated-with-end-stage-renal-disease-and-tophi-burst-a-case-report
#22
JOURNAL ARTICLE
Cahyani Gita Ambarsari, Daffodilone Cahyadi, Lenny Sari, Oryza Satria, Felly Sahli, Thyrza Laudamy Darmadi, Agustina Kadaristiana
Background: Lesch-Nyhan disease (LND) is a rare X-linked recessive inborn error of purine metabolism. Late diagnosis of LND may cause significant morbidity. LND cases have never been reported in Indonesia. Case report: A 15-year-old male who had been diagnosed with cerebral palsy was referred to our hospital due to renal failure requiring emergency dialysis. The patient presented with three classic manifestations of LND: increased uric acid levels, neurological disorders, and self-injurious behaviors. LND was suspected because of an abscess-like lump on the left ankle that was confirmed to be a tophus, which had burst and discharged thick masses containing blood, debris, and white crystal materials...
November 2020: Renal Failure
https://read.qxmd.com/read/31956631/allopurinol-effects-on-residual-renal-function-in-end-stage-renal-disease-patients-undergoing-peritoneal-dialysis-randomized-controlled-trial
#23
JOURNAL ARTICLE
Firouzeh Moeinzadeh, Elham Kabiri Naeini, Mojgan Mortazavi
Objective: There is increasing evidence to show that hyperuricemia may have a pathogenic role in the progression of renal diseases. We performed a prospective, randomized, controlled trial to investigate the renal effects of allopurinol treatment in hyperuricemic patients with end-stage renal disease (ESRD) who undergo peritoneal dialysis. Methods: This was a unicenter, randomized, controlled clinical trial conducted in "Alzahra Hospital, Isfahan, Iran." Patients were randomly assigned into treatment or control group...
October 2019: Journal of Research in Pharmacy Practice
https://read.qxmd.com/read/31628864/comparative-renoprotective-effect-of-febuxostat-and-allopurinol-in-predialysis-stage-5-chronic-kidney-disease-patients-a-nationwide-database-analysis
#24
COMPARATIVE STUDY
Yun-Shiuan O Hsu, I-Wen Wu, Shang-Hung Chang, Cheng-Chia Lee, Chung-Ying Tsai, Chan-Yu Lin, Wan-Ting Lin, Yu-Tung Huang, Chao-Yi Wu, George Kuo, Chih-Yen Hsiao, Hsing-Lin Lin, Chih-Chao Yang, Tzung-Hai Yen, Yung-Chang Chen, Cheng-Chieh Hung, Ya-Chong Tian, Chang-Fu Kuo, Chih-Wei Yang, Gerard F Anderson, Huang-Yu Yang
Hyperuricemia has been associated with chronic kidney disease (CKD) progression. The antihyperuricemic febuxostat's potential renoprotective effect has been demonstrated in stage 1-3 CKD. Large-scale studies comparing the renoprotective potential of febuxostat and allopurinol in advanced CKD are lacking. We exclusively selected 6,057 eligible patients with predialysis stage 5 CKD prescribed either febuxostat or allopurinol using the National Health Insurance Research Database in Taiwan during 2012-2015. There were 69...
May 2020: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/31040373/hyperuricemia-has-increased-the-risk-of-progression-of-chronic-kidney-disease-propensity-score-matching-analysis-from-the-know-ckd-study
#25
JOURNAL ARTICLE
Tae Ryom Oh, Hong Sang Choi, Chang Seong Kim, Eun Hui Bae, Seong Kwon Ma, Su-Ah Sung, Yong-Soo Kim, Kook Hwan Oh, Curie Ahn, Soo Wan Kim
The prevalence of hyperuricemia and chronic kidney disease (CKD) has been steadily increasing. The role of hyperuricemia and efficacy of uric acid-lowering agents against CKD progression remain controversial. This study aimed to evaluate the effect of hyperuricemia and uric acid-lowering agents on the progression of CKD. A total 2042 patients with CKD were analyzed in the KoreaN cohort Study for Outcomes in patients With Chronic Kidney Disease (KNOW-CKD), a prospective cohort study. Patients were classified into quartiles on the basis of their serum uric acid level and the prevalence of advanced CKD was higher in patients with a high uric acid level...
April 30, 2019: Scientific Reports
https://read.qxmd.com/read/30426652/serum-urate-levels-and-therapy-in-adults-treated-with-long-term-dialysis-a-retrospective-cross-sectional-study
#26
JOURNAL ARTICLE
Estella Yeo, Suetonia C Palmer, Peter T Chapman, Christopher Frampton, Lisa K Stamp
BACKGROUND: To estimate the point prevalence of gout, gout treatment, and achievement of target serum urate (SU) among adults treated with long-term dialysis. METHODS: Three secular cohorts of adults receiving dialysis for at least 90 days on 1st February 2017, 1st January 2016 and 1st January 2015 were identified. Medical records were reviewed for SU concentrations. Results were compared between haemodialysis (HD) and peritoneal dialysis (PD), and participants prescribed and not prescribed urate-lowering therapy...
November 13, 2018: Internal Medicine Journal
https://read.qxmd.com/read/30106368/chronic-tubulointerstitial-kidney-disease-in-untreated-adenine-phosphoribosyl-transferase-aprt-deficiency-a-case-report
#27
REVIEW
Benjamin Cochran, Tereza Kovačíková, Kateřina Hodaňová, Martina Živná, Aleš Hnízda, Angela G Niehaus, Alex Bonnecaze, Gowrie Balasubraminiam, Irene Ceballos-Picot, Amret Hawfield, Kendrah Kidd, Stanislav Kmoch, Anthony J Bleyer
Adenine phosphoribosyltransferase (APRT) deficiency (OMIM #614723) is a rare autosomal recessive defect in the purine salvage pathway that causes excessive production of 2,8-dihydroxyadenine, leading to nephrolithiasis and chronic kidney disease (CKD). This case report describes the natural history of CKD in untreated APRT deficiency. We describe a novel APRT mutation (chr16:88877985 G / C; c.195 C>/G; p.His54Asp) presenting with CKD without nephrolithiasis. The patient initially required dialysis, but kidney function improved with allopurinol...
October 2018: Clinical Nephrology
https://read.qxmd.com/read/29554974/renal-dialysis-and-long-term-treatment-of-a-dog-with-kidney-disease-associated-with-canine-leishmaniosis
#28
JOURNAL ARTICLE
Gad Baneth, Gilad Segev, Michal Mazaki-Tovi, Hila Chen, Sharon Kuzi
BACKGROUND: Renal disease is considered the main cause of natural mortality in dogs with canine leishmaniosis. The pathological mechanisms associated with kidney injury in canine leishmaniosis include immune complex glomerulonephritis, tubulointerstitial nephritis and occasionally renal amyloidosis. Proteinuria is a frequent finding in canine leishmaniosis and its quantification by the urine protein-creatinine ratio (UPC) is an important parameter in the staging of canine lesihmaniosis as presented by the LeishVet group...
March 20, 2018: Parasites & Vectors
https://read.qxmd.com/read/29227568/the-effect-of-small-dose-of-topiroxostat-on-serum-uric-acid-in-patients-receiving-hemodialysis
#29
JOURNAL ARTICLE
Yume Nagaoka, Yoshiko Tanaka, Hiroshi Yoshimoto, Rie Suzuki, Kakei Ryu, Mio Ueda, Minako Akiyama, Miho Nagai, Yoshitaka Miyaoka, Eiichiro Kanda, Shinnichi Iwai, Michio Nagaoka, Yoshihiko Kanno
INTRODUCTION: Topiroxostat, a recently developed xanthine oxidase inhibitor, is expected to have fewer adverse effects than allopurinol because it has different mechanism of action from alloprinol. However, its dosage, usage and safety have not been established in patients with impaired renal function or those undergoing dialysis at the development since no studies was conducted in these patients. METHODS: Cross over clinical trial using 3 months of allopurinol and topiroxostat on 27 maintain Japanese HD patients were carried out...
July 2018: Hemodialysis International
https://read.qxmd.com/read/29165620/comparative-effectiveness-of-allopurinol-febuxostat-and-benzbromarone-on-renal-function-in-chronic-kidney-disease-patients-with-hyperuricemia-a-13-year-inception-cohort-study
#30
COMPARATIVE STUDY
Hsu-Wen Chou, Hsien-Tsai Chiu, Ching-Wei Tsai, I-Wen Ting, Hung-Chieh Yeh, Han-Chun Huang, Chin-Chi Kuo
BACKGROUND: Direct comparisons of the effectiveness of allopurinol with that of other urate-lowering agents in chronic kidney disease (CKD) populations, as well as guideline recommendations for clinical practice, are lacking. METHODS: We constructed a pharmacoepidemiology cohort study by including patients from Taiwan's long-term integrated CKD care program to compare the effectiveness among allopurinol, febuxostat and benzbromarone in reducing the risk of progression to dialysis...
September 1, 2018: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/28456346/management-of-gout-and-hyperuricemia-in-ckd
#31
JOURNAL ARTICLE
Ana Beatriz Vargas-Santos, Tuhina Neogi
Hyperuricemia and gout, the clinical manifestation of monosodium urate crystal deposition, are common in patients with chronic kidney disease (CKD). Although the presence of CKD poses additional challenges in gout management, effective urate lowering is possible for most patients with CKD. Initial doses of urate-lowering therapy are lower than in the non-CKD population, whereas incremental dose escalation is guided by regular monitoring of serum urate levels to reach the target level of <6mg/dL (or <5mg/dL for patients with tophi)...
September 2017: American Journal of Kidney Diseases
https://read.qxmd.com/read/28219711/oxidative-stress-inactivates-ecto-5-nucleotidase-by-inhibiting-protein-kinase-c-in-rat-hearts-in-vivo
#32
JOURNAL ARTICLE
Toshio Obata, Michiko Nakashima
Examined in the present study, allopurinol are xanthine oxidase inhibitors for use in rat hearts in vivo dialysis technology and ventricular myocardial intersitial adenosine production can increase. The microdialysis probe was implanted in the left ventricular myocardium of anesthetized rat hearts and the tissue in the vicinity of the dialysis was perfused with Tyrode's solution containing adenosine 5'-monophosphate (AMP) through the dialysis probe at a rate of 1.0ml/min to assess the activity of ecto-5'-nucleotidase...
June 15, 2017: European Journal of Pharmacology
https://read.qxmd.com/read/28153936/the-3-year-incidence-of-gout-in-elderly-patients-with-ckd
#33
JOURNAL ARTICLE
Vivian S Tan, Amit X Garg, Eric McArthur, Ngan N Lam, Manish M Sood, Kyla L Naylor
BACKGROUND AND OBJECTIVES: The risk of gout across CKD stages is not well described. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a retrospective cohort study using linked health care databases from Ontario, Canada from 2002 to 2010. The primary outcome was the 3-year cumulative incidence of gout, on the basis of diagnostic codes. We presented our results by level of kidney function (eGFR≥90 ml/min per 1.73 m2 , 60-89, 45-59, 30-44, 15-29, and chronic dialysis) and by sex...
April 3, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://read.qxmd.com/read/27683090/a-population-pharmacokinetic-model-to-predict-oxypurinol-exposure-in-patients-on-haemodialysis
#34
JOURNAL ARTICLE
Daniel Fb Wright, Matthew P Doogue, Murray L Barclay, Peter T Chapman, Nicholas B Cross, John H Irvine, Lisa K Stamp
PURPOSE: The aims of this study were to characterise the population pharmacokinetics of oxypurinol in patients receiving haemodialysis and to compare oxypurinol exposure in dialysis and non-dialysis patients. METHODS: Oxypurinol plasma concentrations from 6 gout people receiving haemodialysis and 19 people with gout not receiving dialysis were used to develop a population pharmacokinetic model in NONMEM. Deterministic simulations were used to predict the steady-state area under the oxypurinol plasma concentration time curve over 1 week (AUC7days)...
January 2017: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/27267921/musculoskeletal-pain-in-patients-with-chronic-kidney-disease
#35
JOURNAL ARTICLE
Francisco Caravaca, Boris Gonzales, Miguel Ángel Bayo, Enrique Luna
INTRODUCTION: Chronic musculoskeletal pain (CMP) is a very common symptom in patients with chronic kidney disease (CKD), and is associated with a significant deterioration in quality of life. AIMS: To determine the prevalence and clinical characteristics associated with CMP in patients with advanced CKD not on dialysis, and to analyse their relation with other uraemic symptoms and their prognosis significance. MATERIAL AND METHODS: Cross-sectional study to analyse the uraemic symptoms of an unselected cohort of patients with CKD stage 4-5 pre-dialysis...
July 2016: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
https://read.qxmd.com/read/26855510/sevelamer-is-an-effective-drug-in-treating-hyperphosphatemia-due-to-tumor-lysis-syndrome-in-children-a-developing-world-experience
#36
JOURNAL ARTICLE
Dilraj Kaur Kahlon, Veronique Dinand, Satya Prakash Yadav, Anupam Sachdeva
We report here a study on efficacy of sevelamer hydrochloride in treating hyperphosphatemia due to tumor lysis syndrome (TLS) in a developing world setting. Twenty one children with hyperphosphatemia due to TLS were included. All received hyper-hydration, allopurinol and sevelamer. Efficacy was assessed by decrease in serum phosphate level, calcium-phosphate product and TLS score as per Cairo Bishop definition. Four children who underwent dialysis were excluded from analysis. Among the remaining 17 patients with hyperphosphatemia, laboratory TLS was recorded in 15 patients and clinical TLS in five...
March 2016: Indian Journal of Hematology & Blood Transfusion
https://read.qxmd.com/read/26453097/allopurinol-and-kidney-function-an-update
#37
REVIEW
Lisa K Stamp, Peter T Chapman, Suetonia C Palmer
Allopurinol is the most commonly used urate lowering therapy in the management of gout. Despite the fact that it has been available for over 40 years there is ongoing debate about optimal allopurinol dosing in gout patients with chronic kidney disease. Given that gout is common in patients with renal impairment, clinicians need to be aware of the relationships between serum urate and kidney function as well as the effects of allopurinol on kidney function and vice versa. The use of allopurinol in patients on dialysis is an understudied area...
January 2016: Joint, Bone, Spine: Revue du Rhumatisme
https://read.qxmd.com/read/26446847/drug-dosage-adjustment-in-hospitalized-patients-with-renal-impairment-at-tikur-anbessa-specialized-hospital-addis-ababa-ethiopia
#38
JOURNAL ARTICLE
Henok Getachew, Yewondwossen Tadesse, Workineh Shibeshi
BACKGROUND: Dose adjustment for certain drugs is required in patients with reduced renal function to avoid toxicity as many drugs are eliminated by the kidneys. The aim of this study was to assess whether appropriate dosage adjustments were made in hospitalized patients with renal impairment. METHODS: A prospective cross-sectional study was carried out in the internal medicine wards of Tikur Anbessa Specialized Hospital. All patients with creatinine clearance ≤ 59 ml/min admitted to hospital between April and July, 2013 were included in the analysis...
2015: BMC Nephrology
https://read.qxmd.com/read/26380104/recurrence-of-crystalline-nephropathy-after-kidney-transplantation-in-aprt-deficiency-and-primary-hyperoxaluria
#39
REVIEW
Guillaume Bollée, Pierre Cochat, Michel Daudon
PURPOSE OF REVIEW: To provide transplant physicians with a summary of the pathogenesis and diagnosis of adenine phosphoribosyl transferase (APRT) deficiency and primary hyperoxaluria and, focussed on kidney transplantation, and to discuss interventions aimed at preventing and treating the recurrence of crystalline nephropathy in renal transplant recipients. SOURCE OF INFORMATION: Pubmed literature search. SETTING: Primary hyperoxaluria and APRT deficiency are rare inborn errors of human metabolism...
2015: Canadian Journal of Kidney Health and Disease
https://read.qxmd.com/read/26037787/ten-year-experience-of-using-a-novel-metabolic-protocol-in-off-pump-coronary-artery-bypass-revascularization
#40
JOURNAL ARTICLE
David J Perkowski, Susan Wagner, Kathryn Muller, Joseph R Schneider, J A St Cyr
PURPOSE: Assessment of both short- and long-term outcomes in patients undergoing off-pump coronary artery bypass using a perioperative metabolic protocol. METHODS: A total of 975 of 995 adult patients underwent coronary artery bypass 'off-pump' from 1997 through 2006. Patients presenting in cardiogenic shock were excluded from this assessment. A perioperative metabolic protocol, which included the implementation of allopurinol, insulin supplementation, magnesium sulfate, supplemental corticosteroids, milrinone, norepinephrine (prn), aspirin, clopidogrel, statins and β-blockers, was used in these patients...
December 2015: Therapeutic Advances in Cardiovascular Disease
keyword
keyword
164040
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.